kmup-1 and Vascular-Diseases

kmup-1 has been researched along with Vascular-Diseases* in 1 studies

Other Studies

1 other study(ies) available for kmup-1 and Vascular-Diseases

Article	Year
KMUP-1 protects against streptozotocin-induced mesenteric artery dysfunction via activation of ATP-sensitive potassium channels. Pharmacological reports : PR, 2018, Volume: 70, Issue:4 Diabetes mellitus is a metabolic disorder characterized by chronic hyperglycemia accompanied by impaired vascular and endothelial function. Activation of ATP-sensitive potassium (K. Rats were divided into three groups: control, STZ (65 mg/kg, ip) and STZ + KMUP-1 (5 or 10 mg/kg/day, ip). MA reactivity was measured by dual wire myograph. MA smooth muscle cells (MASMCs) were enzymatically dissociated and the K. STZ decreased MA K. KMUP-1 prevents STZ impairment of MA reactivity, eNOS levels and K Topics: Animals; Diabetes Mellitus, Experimental; Dose-Response Relationship, Drug; KATP Channels; Male; Membrane Potentials; Mesenteric Arteries; Myocytes, Smooth Muscle; Nitric Oxide Synthase Type III; Piperidines; Potassium; Rats; Time Factors; Vascular Diseases; Xanthines	2018

Article

Year

KMUP-1 protects against streptozotocin-induced mesenteric artery dysfunction via activation of ATP-sensitive potassium channels.

Pharmacological reports : PR, 2018, Volume: 70, Issue:4

Diabetes mellitus is a metabolic disorder characterized by chronic hyperglycemia accompanied by impaired vascular and endothelial function. Activation of ATP-sensitive potassium (K. Rats were divided into three groups: control, STZ (65 mg/kg, ip) and STZ + KMUP-1 (5 or 10 mg/kg/day, ip). MA reactivity was measured by dual wire myograph. MA smooth muscle cells (MASMCs) were enzymatically dissociated and the K. STZ decreased MA K. KMUP-1 prevents STZ impairment of MA reactivity, eNOS levels and K

Topics: Animals; Diabetes Mellitus, Experimental; Dose-Response Relationship, Drug; KATP Channels; Male; Membrane Potentials; Mesenteric Arteries; Myocytes, Smooth Muscle; Nitric Oxide Synthase Type III; Piperidines; Potassium; Rats; Time Factors; Vascular Diseases; Xanthines

2018